We are live on ! Find out more
DMRA

Damora Therapeutics, Inc. Ordinary Shares
DMRA

65 hedge funds and large institutions have $1.45B invested in Damora Therapeutics, Inc. Ordinary Shares in 2026 Q1 according to their latest regulatory filings, with 51 funds opening new positions, 13 increasing their positions, 0 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

2,116% more capital invested

Capital invested by funds: $65.5M → $1.45B (+$1.39B)

1,600% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 3

400% more funds holding in top 10

Funds holding in top 10: 1 → 5 (+4)

261% more funds holding

Funds holding: 18 → 65 (+47)

23.41% more ownership

Funds ownership: 69.45% → 92.86% (+23%)

Holders
65
Holders Change
+47
Holders Change %
+261.11%
% of All Funds
0.8%
Holding in Top 10
5
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+400%
% of All Funds
0.06%
New
51
Increased
13
Reduced
–
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$226M
2
FFM
Fairmount Funds Management
Pennsylvania
+$224M
3
ACA
Avoro Capital Advisors
New York
+$97.2M
4
VA
VR Adviser
New York
+$92.6M
5
FIS
FCPM III Services
Netherlands
+$62.7M

Top Sellers

Rank Fund Capital Flow
1
JG
Jain Global
New York
-$2.77M
2
SPC
Sigma Planning Corp
Michigan
-$334K
3
SWM
SHP Wealth Management
Massachusetts
-$575
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$234M +$226M +8,806,603 +3,687%
FFM
2
Fairmount Funds Management
Pennsylvania
$226M +$224M +8,713,000 New
ACA
3
Avoro Capital Advisors
New York
$98M +$97.2M +3,783,000 New
VA
4
VR Adviser
New York
$93.3M +$92.6M +3,603,595 New
FIS
5
FCPM III Services
Netherlands
$63.2M +$62.7M +2,441,000 New
RCM
6
RA Capital Management
Massachusetts
$62.1M +$61.7M +2,399,310 New
Janus Henderson Group
7
Janus Henderson Group
United Kingdom
$61.4M +$60.7M +2,360,957 +135,765%
Viking Global Investors
8
Viking Global Investors
Connecticut
$59.9M +$59.4M +2,311,082 New
BG
9
Bellevue Group
Switzerland
$59.5M +$59.1M +2,298,000 New
RCP
10
Remedium Capital Partners
Florida
$53M +$49.5M +1,925,000 +1,598%
CC
11
Commodore Capital
New York
$50.2M +$49.8M +1,939,000 New
CAM
12
Cormorant Asset Management
Massachusetts
$39.5M +$39.2M +1,525,000 New
Balyasny Asset Management
13
Balyasny Asset Management
Illinois
$37.5M +$37.2M +1,448,000 New
ACM
14
AH Capital Management
California
$32M +$31.8M +1,236,157 New
PA
15
Perceptive Advisors
New York
$31.7M +$31.4M +1,223,000 New
Point72 Asset Management
16
Point72 Asset Management
Connecticut
$30.9M +$27.9M +1,084,708 +995%
Wellington Management Group
17
Wellington Management Group
Massachusetts
$27.4M +$27.2M +1,058,000 New
SL
18
Siren LLC
Connecticut
$23.3M +$23.1M +900,000 New
B
19
Braidwell
Connecticut
$23.2M +$23M +894,846 New
VPC
20
Vestal Point Capital
New York
$15.5M +$15.4M +600,000 New
Blackstone Inc
21
Blackstone Inc
New York
$13M +$12.9M +503,522 New
Millennium Management
22
Millennium Management
New York
$12.2M +$12.1M +471,646 New
AAA
23
Affinity Asset Advisors
New York
$11.7M +$11.6M +450,000 New
IC
24
Ikarian Capital
Texas
$8.69M +$1.29M +50,000 +18%
Qube Research & Technologies (QRT)
25
Qube Research & Technologies (QRT)
United Kingdom
$7.32M +$7.26M +282,436 New
1
2 3

DMRA Hedge Fund Activity: Q1 2026 in Review

65 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Damora Therapeutics, Inc. Ordinary Shares (DMRA) for Q1 2026, worth a combined $1.45B — up 2,116% from $65.5M a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new DMRA positions and 3 closed out — a net gain of 48 holders — while 13 added to existing stakes and 0 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $226M. The largest seller was Jain Global, exiting entirely with an estimated $2.77M sold.

  • 65 institutional investors held Damora Therapeutics, Inc. Ordinary Shares (DMRA) as of Q1 2026, up from 18 in Q4 2025.
  • Funds reported $1.45B of Damora Therapeutics, Inc. Ordinary Shares stock for Q1 2026, up 2,116% quarter-over-quarter.
  • 51 funds opened new Damora Therapeutics, Inc. Ordinary Shares positions in Q1 2026 and 3 closed out, a net change of +48 holders.
  • The largest Damora Therapeutics, Inc. Ordinary Shares buyer in Q1 2026 was Fidelity Investments, an estimated $226M added.
  • The largest Damora Therapeutics, Inc. Ordinary Shares seller in Q1 2026 was Jain Global, an estimated $2.77M sold.

Based on aggregated 13F filings for Q1 2026.